LORVIQUA

(lorlatinib)

Find LORVIQUA medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

LORVIQUA Quick Finder

The Summary of Product Characteristics (SPC) for Lorviqua, film-coated tablets (25mg or 100mg) is available here.

Lorviqua (lorlatinib) as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:

alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
crizotinib and at least one other ALK TKI.

Didn’t find what you were looking for?

Contact us

Call 01 58 07 34 40*

*Contact Medical Information. 09h - 18h Monday to Friday.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to a Pfizer product, click on the link:
www.pfizersafetyreporting.com
If you cannot use the above website, please contact Pfizer pharmacovigilance at [email protected].

Governmental website

You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr